General information:
Substance group: direct oral anticoagulant (DOAK) / selective factor xa inhibitor ATC: B01AF03
Trade name: Lixiana®
available dosages: Film tablets 15 / 30 / 60 mg
Reference ranges:
1x60mg
Cmax (1-2h after ingestion): 170 ng/mL (120-250 ng/mL)
Trough level (before the next intake): 22 ng/mL (10-40 ng/mL)
1x30mg
Cmax (1-2h after ingestion): 84 ng/mL (60-120 ng/mL)
Trough level (before next intake): 12 ng/mL (4-20 ng/mL)
Toxic dose: not established yet
Sampling:
Material: Citrate Plasma (Monovette Green) Minimum volume for analysis: 500µl
Recommendation: trough level (directly before the next intake)
Request (internal): … Requirement (external): after consultation (+49 221 478 5066)
Analytics:
Test principle: liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)
Protein precipitation with acetonitrile, chromatographic separation, mass spectrometry
Analysis according to mass charge ratio
Analysis system: triple stage Quadrupol mass spectrometer (LC-MS/MS)
Findings release: on the same working day, via LIMS
Medication given in Intensive Care – Pharmacotherapy and TDM
An interdisciplinary challenge